Unicycive Therapeutics Readies for Major Investor Events
Unicycive Therapeutics, Inc. (NASDAQ: UNCY), a pioneering biotechnology firm based in Los Altos, California, is excited to share that its CEO, Shalabh Gupta, M.D., will participate in two significant investor events this December. These occasions are designed for investors to gain insights into Unicycive's groundbreaking work in treating kidney diseases.
Upcoming Investor Engagements
Piper Sandler 37th Annual Healthcare Conference
The first event, the Piper Sandler 37th Annual Healthcare Conference, is scheduled for Wednesday, December 3, 2025, at 10:00 a.m. ET. This conference is an excellent opportunity for stakeholders to hear directly from the management about the company's ongoing efforts and key developments.
Noble Capital Markets Virtual Presentation
Following that, Unicycive will host a presentation at the Noble Capital Markets Virtual Presentation on Wednesday, December 10, 2025, at 10:00 a.m. PT. This session will provide further insights into the company's innovative treatments and future plans.
Engaging with the Investors
Investors interested in these events can follow the live and archived presentations on Unicycive's website under the Investors section. This transparency is part of Unicycive’s commitment to keeping stakeholders informed about the latest developments affecting the company.
Innovative Kidney Disease Treatments
At the forefront of Unicycive's mission is its lead investigational treatment, oxylanthanum carbonate. This novel phosphate-binding agent is currently under review by the U.S. Food and Drug Administration (FDA) for treating hyperphosphatemia in patients with chronic kidney disease who are on dialysis. The company is dedicated to nurturing therapies that significantly improve the quality of life for kidney disease patients.
Introducing UNI-494
In addition to oxylanthanum carbonate, Unicycive is also advancing its second investigational treatment, UNI-494. This treatment aims to address acute kidney injury-related conditions and has received orphan drug designation from the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients. Recently, UNI-494 completed a Phase 1 dose-ranging safety study in healthy volunteers, showcasing the company's commitment to rigorous research and patient safety.
Stay Connected with Unicycive Therapeutics
To learn more about Unicycive Therapeutics’ innovative solutions and ongoing projects, interested parties are encouraged to visit the company’s official site. Regular updates, news, and developments will be posted, along with engaging content highlighting the journey and achievements of this impactful company.
Contacting Unicycive Therapeutics
**Investor Contact:**
Kevin Gardner
LifeSci Advisors
Email: kgardner@lifesciadvisors.com
**Media Contact:**
Layne Litsinger
Real Chemistry
Email: llitsinger@realchemistry.com
Frequently Asked Questions
1. What is the focus of Unicycive Therapeutics?
Unicycive Therapeutics focuses on developing innovative therapies for kidney diseases, addressing critical treatment needs.
2. Who will represent Unicycive at the investor events?
Shalabh Gupta, M.D., the Chief Executive Officer, will represent Unicycive at the upcoming investor events.
3. When is the Piper Sandler Annual Healthcare Conference taking place?
The Piper Sandler 37th Annual Healthcare Conference is set for December 3, 2025, at 10:00 a.m. ET.
4. What are oxylanthanum carbonate and UNI-494?
Oxylanthanum carbonate is a phosphate-binding agent under FDA review, while UNI-494 is an investigational treatment for acute kidney injury with orphan drug designation.
5. How can stakeholders stay updated on company news?
Stakeholders can stay updated by visiting Unicycive's official website for the latest news, developments, and information on innovative treatments.